Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

VJVirtual | ANNOUNCE: doxorubicin + olaratumab in advanced soft tissue sarcomas

Robin Jones, MBBS, MRCP, MD (Res), Royal Marsden NHS Foundation Trust, London, UK, updates us on recent results published from the ANNOUNCE Phase III study which evaluated the addition of olaratumab to doxorubicin in patients with advanced/metastatic soft tissue sarcoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.